Roles of the FGF-FGFR Signaling System in Cancer Development and Inflammation

Wiedlocha, Antoni G; Haugsten, Ellen Margrethe; Zakrzewska, Małgorzata

doi:10.3390/cells10092231

Cited by 14 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been widely known that the systematic inflammation response is closely related with the occurrence and development of tumors. The detailed internal mechanisms have been deeply explored and introduced in previous literatures[ 8 , 33 - 35 ]. The neutrophils, lymphocytes, platelets, monocytes and C-reactive protein are all common inflammatory biomarkers and a great number of studies have revealed the prognostic role of NLR, PLR, LMR and GPS in tumors.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte ratios and Glasgow prognostic score in osteosarcoma: A meta-analysis

Peng¹,

Li²,

Li³

2022

WJCC

View full text Add to dashboard Cite

BACKGROUND Some studies investigated the prognostic role of several blood biomarkers, including the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR) and Glasgow prognostic score (GPS), in osteosarcoma, but their results were inconsistent with each other. AIM To identify the prognostic value of NLR, PLR, LMR and GPS in osteosarcoma patients through reviewing relevant studies. METHODS The PubMed, EMBASE, Web of Science and CNKI databases were searched up to October 2, 2021. The primary and second outcomes were overall survival (OS) and disease-free survival (DFS), respectively. The hazard ratios (HRs) with 95% confidence intervals (CIs) were combined to assess the association between these indicators and prognosis of osteosarcoma patients. RESULTS A total of 13 studies involving 2087 patients were eventually included. The pooled results demonstrated that higher NLR and GPS were significantly associated with poorer OS (HR = 1.88, 95%CI: 1.38-2.55, P < 0.001; HR = 2.19, 95%CI: 1.64-2.94, P < 0.001) and DFS (HR = 1.67, 95%CI: 1.37-2.04, P < 0.001; HR = 2.50, 95%CI: 1.39-4.48, P < 0.001). However, no significant relationship of PLR and LMR and OS ( P = 0.085; P = 0.338) and DFS ( P = 0.396; P = 0.124) was observed. CONCLUSION Higher NLR and GPS were related with worse prognosis and might serve as novel prognostic indicators for osteosarcoma patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of neutrophil/lymphocyte, platelet/lymphocyte, lymphocyte/monocyte ratios and Glasgow prognostic score in osteosarcoma: A meta-analysis

Peng¹,

Li²,

Li³

2022

WJCC

View full text Add to dashboard Cite

show abstract

“…In mice and humans, the Fibroblast Growth Factor (FGF) family is composed of 22 polypeptides that act as secreted signaling proteins (FGF1-10, FGF16-23) or as receptor-independent intracellular factors (FGF11-14), with the latter being mainly involved in neuronal development and in regulating the electrical excitability of neurons [ 31 , 32 ]. Secreted FGFs are grouped into 6 subfamilies according to phylogenetic analysis and sequence homology.…”

Section: The Fibroblast Growth Factor (Fgf)/fgf Receptor (Fgfr) Systemmentioning

confidence: 99%

“…The subfamilies FGF1/2/5, FGF3/4/6, FGF7/10/22, FGF8/17/18, and FGF9/16/20 are known as canonical FGFs and act as local paracrine signaling molecules. The FGF19/21/23 subfamily comprises hormone-like FGFs acting as endocrine factors that control metabolic homeostasis [ 31 , 33 , 34 ]. Both canonical and hormone-like FGFs mediate their biological functions by activating cell surface tyrosine kinase (TK) receptors (FGFRs), which are encoded by four distinct genes ( FGFR1-4 ) in mammals [ 31 , 33 ].…”

Section: The Fibroblast Growth Factor (Fgf)/fgf Receptor (Fgfr) Systemmentioning

confidence: 99%

“…The FGF19/21/23 subfamily comprises hormone-like FGFs acting as endocrine factors that control metabolic homeostasis [ 31 , 33 , 34 ]. Both canonical and hormone-like FGFs mediate their biological functions by activating cell surface tyrosine kinase (TK) receptors (FGFRs), which are encoded by four distinct genes ( FGFR1-4 ) in mammals [ 31 , 33 ]. Structurally, FGFRs present an extracellular domain, a transmembrane domain, and a cytoplasmic TK tail, which is responsible for FGF-related signaling.…”

Section: The Fibroblast Growth Factor (Fgf)/fgf Receptor (Fgfr) Systemmentioning

confidence: 99%

“…Indeed, it is involved from the earliest phases of embryonic development by taking part in mesoderm patterning; moreover, by regulating mesenchymal-epithelial communications, the FGF/FGFR system is essential for organogenesis. Furthermore, FGFs/FGFRs exert homeostatic functions in adults, being involved in tissue repair and remodeling processes [ 31 , 34 ].…”

Section: The Fibroblast Growth Factor (Fgf)/fgf Receptor (Fgfr) Systemmentioning

confidence: 99%

See 2 more Smart Citations

Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives

Loda

Turati

Semeraro

et al. 2022

IJMS

View full text Add to dashboard Cite

Ocular tumors are a family of rare neoplasms that develop in the eye. Depending on the type of cancer, they mainly originate from cells localized within the retina, the uvea, or the vitreous. Even though current treatments (e.g., radiotherapy, transpupillary thermotherapy, cryotherapy, chemotherapy, local resection, or enucleation) achieve the control of the local tumor in the majority of treated cases, a significant percentage of patients develop metastatic disease. In recent years, new targeting therapies and immuno-therapeutic approaches have been evaluated. Nevertheless, the search for novel targets and players is eagerly required to prevent and control tumor growth and metastasis dissemination. The fibroblast growth factor (FGF)/FGF receptor (FGFR) system consists of a family of proteins involved in a variety of physiological and pathological processes, including cancer. Indeed, tumor and stroma activation of the FGF/FGFR system plays a relevant role in tumor growth, invasion, and resistance, as well as in angiogenesis and dissemination. To date, scattered pieces of literature report that FGFs and FGFRs are expressed by a significant subset of primary eye cancers, where they play relevant and pleiotropic roles. In this review, we provide an up-to-date description of the relevant roles played by the FGF/FGFR system in ocular tumors and speculate on its possible prognostic and therapeutic exploitation.

show abstract